Biosplice Announces First Patient Dosed in Phase 2 Cirtuvivint Trial
Biosplice Therapeutics has initiated a Phase 2 clinical trial of its CLK/DYRK kinase inhibitor, cirtuvivint, in patients with advanced...
OBI Pharma Announces FDA IND Clearance for Phase 1/2 Study of OBI-902, a TROP-2 Targeting ADC
OBI Pharma, a clinical-stage oncology company, received FDA clearance for an Investigational New Drug (IND) application for OBI-902, a...
Neurocrine Starts Phase 3 Trial of NBI-1117568 for Schizophrenia
Nxera Pharma’s partner, Neurocrine Biosciences, has launched a Phase 3 trial for NBI-1117568, an oral M4 selective receptor agonist,...
DecisionDx®-Melanoma Test Outperforms in Low-Risk SLN Positivity
A new study in Cancer Diagnosis & Prognosis shows that Castle Biosciences’ DecisionDx–Melanoma test outperforms current standards for identifying...
Gazya as a New Option for Lupus Nephritis
The American College of Rheumatology (ACR) updated its lupus nephritis (LN) treatment guidelines, emphasizing triple therapy with Benlysta or...
NeuroSigma’s Monarch eTNS System ADHD Trial for Children with Fetal Alcohol Syndrome at UCLA
NeuroSigma, Inc. announced a new clinical trial for its Monarch external Trigeminal Nerve Stimulation (eTNS) device. The trial will...
Oncocyte’s Promising Clinical Trial Update
Oncocyte Corporation (Nasdaq: OCX) is preparing to launch a pivotal clinical trial for its organ transplant rejection monitoring test...
ABIVAX Completes Enrollment for Phase 3 Ulcerative Colitis Trial
Abivax completed enrollment for its Phase 3 ABTECT trials of obefazimod, a treatment for moderately to severely active ulcerative...
Oncocyte’s Assay Demonstrates Clinical Validity
Oncocyte Corporation announced positive data from a four-year study at Charité University in Berlin, validating its blood-based transplant rejection...
Incyclix Bio’s INX-315 Gets FDA Fast Track for Ovarian Cancer
Incyclix Bio‘s CDK2 inhibitor, INX-315, has received FDA Fast Track designation for treating CCNE1-amplified, platinum-resistant/refractory ovarian cancer. This designation...